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THE MULTILEVEL REGULATION OF CD95 SIGNALING OUTCOME
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CD95, also called Fas or APO-1, was the first death receptor (DR) identified and characterized. Studies on CD95 receptor signal-
ing revealed the versatile principles of cell fate regulation via DR. DRs could exert both pro- and anti-apoptotic effects depending 
on clustering, internalization or signaling thresholds and other extracellular signals. It became clear that molecular network regu-
lating cell death and survival is under the multilevel control. In this Review we focus on the regulation of CD95 signaling and provide 
brief analysis of molecular switches of its pro- and antiapoptotic functions. At least five levels of life-death cell regulation via 
CD95 could be tracked: extracellular, membrane, DISC, mitochondrial, and miRNA. The cellular outcome of signaling via DRs 
depends on other extracellular signals and availability of different intracellular components of signal transduction pathways. This 
article is part of a Special Issue entitled “Apoptosis: Four Decades Later”.
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�tarting from the concept of natural cell death pro-
posed in �8�� �y Carl Vogt and the first morphological 
documentation of programmed cell death provided 
in �88� �y Walther Flemming till the introduction of the 
term of apoptosis in ��7� our knowledge of this pro-
cess was restrained to descriptive o�servations [�]. 
The key milestones on the way to understanding the 
molecular network that regulate cellular life and death 
decisions were the discovery of Bcl-� family proteins� 
revealing the role of p�� in apoptosis and characteriza-
tion of CD��-mediated signaling pathways. Actually� 
CD��� also called Fas or APO-�� was the first death 
receptor �DR� identified and characterized. 
There are multiple examples of novel antigen 
identification using monoclonal anti�odies �mA�s�. 
Hy�ridoma technology of mA�s generation includes 
an element of discovery� especially when whole cells 
or cellular components are used for immunization. 
We have many examples of novel antigen identification 
independently in different la�oratories that used this 
approach. One of such examples is CD�� discovery.
Apoptosis got special attention from oncologists� 
since revolving tumor cell fate from proliferation 
to apoptosis seemed to �e an ideal scenario for anti-
tumor therapy. In fact the paper of Kerr et al. [�] with 
definition of term apoptosis was pu�lished in the British 
Journal of Cancer. The general idea of ��8� year pu�-
lication of Peter Kramer la�oratory at German Cancer 
Research Center in Heidel�erg was to characterize 
cell surface molecules involved in control of growth 
of malignant lymphocytes [�]. Among mA�s against 
the human B lympho�last cell line �KW6.� they iden-
tified one mA� anti-APO-� that �locks growth and 
induces apoptosis of target cells in vitro. Moreover� 
anti-APO-� was a�le to induce in vivo apoptosis 
of Burkitt lymphoma cell line BJAB xenotransplant [�]. 
In parallel� �hin Yonehara et al. [�] pu�lished a paper 
on a new Fas antigen �F�-7-associated surface anti-
gen� involved in induction of cell death. They acciden-
tally found mA� that had a cytopathic activity against 
human F�-7 cells [�]. It should �e noted that practically 
at the same time the mA� IPO-� against lymphocyte 
activation antigen was developed at the Institute 
of Pro�lems of Oncology in Kyiv �Ukraine� [��7]. In this 
case a mouse was immunized with B-lympho�lastoid 
cell line RPMI-�788 [�]. During Fifth International 
Workshop on White Cell Differentiation Antigens it was 
shown that mA�s Apo-�� anti-Fas� IPO-� and also 
7C�� recognize closely related epitopes on antigen 
that in ���� received an international nomenclature 
CD�� [8]. Expression cloning of CD�� cDNA [�] 
showed that this antigen �elongs to TNF-receptor su-
perfamily �TNFR�F� that according to HUGO Gene No-
menclature Committee up to date em�races �6 genes 
�http://www.genenames.org/genefamily/tnfrsf.php�.
The mem�ers of TNFR�F are type-I transmem-
�rane proteins with N-terminal extracellular ligand-
�inding part� single transmem�rane region and C-ter-
minal cytoplasmic tail [�� ��]. The hallmark of TNFR�F 
proteins is up to six cysteine-rich domains �CRDs� 
that are typically defined �y six highly conserved cys-
teines� which formed three intrachain disulfide �onds 
[��]. CD�� possess three CRDs� with ligand contacts 
occur mainly in the second and third CRDs [��]. The 
characteristic feature of CD�� and five more mem�ers 
of TNFR�F �TNFR�/CD���a� DR�� DR�/TRAILR�� 
DR�/TRAILR� and DR6� is the presence of moderately 
well conserved region of a�out 8� residues called the 
“death domain” �DD� in cytoplasmic part of the recep-
tor [��]. In addition to the full length mRNA� at least 
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five alternatively spliced isoforms encoding solu�le 
CD�� lacking transmem�rane region have �een identi-
fied [��� ��].
CD�� was first identified on cells of hematopoietic 
system [�� �]. While expressed on minority of resting 
T� B� NK cells� and monocytes� this antigen is strongly 
upregulated after cell activation. Moreover� it is widely 
expressed on cell lines of T� B� NK and myeloid origin� 
and also on some primary leukemia and lymphoma cells 
[7� ��]. �ince it was shown that CD�� is also expressed 
in liver� pancreas� heart� kidneys and �rain� the initial idea 
to use anti-CD�� anti�odies as possi�le anticancer agent 
was not followed up. Nevertheless� studies of CD��-me-
diated signal transduction pathways and their modulation 
revealed the common multilevel regulation of “death 
receptors” functions that determine cell fate. 
Crosslinking of CD�� with its natural ligand CD��L/
CD�78 or with agonistic anti�odies may have a diffe-
rent cellular outcome. CD�� ligation exerts the cyto-
toxic effect �y inducing apoptosis and even necrosis 
[�� ��� �6]. Conversely� CD�� was shown to promote 
cell proliferation� migration� differentiation� liver and 
peripheral nerve regeneration� etc. [�7���]. CD�� has 
�een initially cloned as a DR and is classified as a tu-
mor suppressor gene. However� it also promotes early 
carcinogenesis [�����]. CD�� expression was found 
on neoplastic cells in tumors of different histogenesis 
[��]� �ut many of these cells lack sensitivity to CD��-
Figure. �chematic representation of multilevel regulation of CD�� signaling outcome. CD��-mediated signaling could result in cell 
survival or apoptosis depending on fine �alance of molecular switches in cells� and activation or inhi�ition of a range of signaling 
pathways upon receptor ligation. The initial event for CD��-mediated signaling is trimerization �y specific ligand CD��L/CD�78. The 
mem�rane-�ound CD��L is essential for the cytotoxic activity� while solu�le CD��L promote non-apoptotic pathways. The initial 
concentration of CD��L also contri�utes to the cellular decisions for CD��-induced life and death. After ligation CD�� receptors are 
internalized through clathrin-mediated endocytosis and delivered to the early endosomal compartment� where most of the Death-
Inducing-�ignaling-Complex �DI�C� formation occurs. Procaspase-8� c-FLIP proteins and their cleavage products play a prominent 
role in the regulation of CD��-mediated pro-apoptotic as well as survival signaling. The ratio of c-FLIP to procaspase-8 at the DI�C 
plays the central role in the regulation of MAPK induction �y defining the amount of active caspase-8/�� generated at the DI�C. Ac-
tive caspases 8 and �� initiate a signaling cascade that results in activation of the effector caspases �caspases-�� -6� and -7� either 
�y directly processing the effector caspases themselves �type I cells� or �y engaging the mitochondrial death pathway mediated 
�y the cleavage of Bid protein �type II cells�. XIAP �X-linked inhi�itor of apoptosis� could directly �ind to caspase-�� -7 and -� and 
�y this �lock their function. The release of proapoptotic proteins from the mitochondria such as cytochrome c �Cyt c� and �MAC 
�XIAP inhi�itor� promotes effector caspase activation and apoptosis. CD�� signaling outcome was shown to �e regulated �y miR-
NAs. miRNA-�� indirectly targets the CD�� expression in cancer cells� and antiapoptotic cytosolic protein Fas Apoptosis Inhi�itory 
Molecule �FAIM� is an immediate miRNA-���� target
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mediated cytotoxic signal [��]. Despite the reports 
on loss-of-function mutations in CD95 gene� they can-
not account for all cases of resistance to CD��-me-
diated apoptosis in tumors [��� ��]. Detailed dissec-
tion of CD��-mediated signal transduction pathways 
revealed the multilevel regulation of this dual-function 
receptor signaling in normal and malignant cells. Dif-
ferent levels of CD�� signaling regulation and outcome 
are presented in schematic form �Figure�.
EXTRACELLULAR LEVEL
The initial event for CD��-mediated signaling 
is trimerization �y specific ligand [�6]. In the mean-
while� the ligand-independent preassem�led receptor 
complex formation through highly specific preligand 
assem�ly domain �PLAD� in the mem�rane-distal 
cystein domain was also reported [�7� �8]. CD��L/
CD�78 is a preassociated homotrimer of type II mem-
�rane protein that can �e released in solu�le form after 
cleavage �etween �er-��6 and Leu-��7 �y metallo-
proteinases [��� ��]. Ligand contacts with CD�� occur 
mainly in the second and third CRDs [��]. It has �een 
demonstrated that mem�rane-�ound CD��L is es-
sential for the cytotoxic activity� while solu�le CD��L 
promote non-apoptotic pathways [��]. Moreover� the 
initial concentration of CD��L is one of the most im-
portant factors contri�uting to the cellular decisions for 
CD��-induced life and death [��]. Many tumor cells 
acquired protective mechanisms to avoid elimination 
�y CD���CD��L system� one of which is downregula-
tion of CD95 expression or CD95 mutation [��]. These 
could �e regarded as an extracellular level of CD�� sig-
naling regulation.
MEMBRANE LEVEL
After ligation of CD�� �y CD��L or agonistic 
anti�odies� receptors are internalized through 
clathrin-mediated endocytosis and delivered to the 
early endosomal compartment� where most of the 
Death-Inducing-�ignaling-Complex �DI�C� formation 
occurs [��]. Both internalization of the CD�� receptor 
and localization to the endosomal compartment are 
required steps for efficient DI�C assem�ly� amplifica-
tion of the signal� and execution of apoptosis [��]. The 
early detecta�le events after CD�� ligation are forma-
tion of �ignaling Protein Oligomerization Transduction 
�tructures ��POT�� [��] and �D�-sta�le aggregates 
of receptors [�6]. These processes involve palmi-
toylation of the mem�rane proximal Cys-��� in the 
CD�� cytoplasmic region [�6� �7]. The post-trans-
lational modification of CD�� �y palmitoylation is the 
targeting signal for receptor localization to lipid rafts. 
Palmitoylation is required for the CD�� redistri�ution 
to actin and ezrin-mediated cytoskeleton associations� 
which are necessary for the efficient DI�C assem�ly 
and receptor internalization [�7].
The conserved extracellular glycosphingolipid-
�inding motif �GBM� of CD�� was identified as one 
of the regulatory elements in the selection of its in-
ternalization route. This motif is required for clathrin-
mediated CD�� internalization� which allows the 
transduction of apoptotic signal. The loss of function 
of GBM switches the activated CD�� to an alternative 
internalization ezrin-dependent route and promotes 
its non-death functions [�8].
Cholesterol- and sphingolipid-rich mem�rane 
domains �lipid rafts� were shown to �e very important 
for effective induction of DR-mediated apoptosis. Re-
cently� the mem�rane level of DR-signaling regulation 
appeared in the focus of anti-cancer drug develop-
ment. An increasing num�er of antitumor drugs have 
�een found to induce apoptosis through recruitment 
of CD�� into mem�rane rafts� and some of these 
compounds accumulated in raft mem�rane domains. 
Edelfosine� which is their alkyl-lysophospholipid ana-
logue� was the first antitumor drug reported to induce 
apoptosis in cancer cells through co-clustering of lipid 
rafts and CD�� DR [��]. It was shown that pharmaco-
logically modulated mem�rane microdomains can act 
as scaffolds for CD�� death signaling [��]. Therefore� 
the development of drugs� which modulate CD�� ac-
cumulation in lipid rafts� have �ecome a promising task 
for cancer chemotherapy.
DISC LEVEL
DI�C signalosome serves as third level of CD��-
mediated pathways regulation with multiple molecular 
switches. Indeed DI�C formation is necessary not 
only for induction of apoptosis� �ut also for initiation 
of survival pathways. Interactions �etween CD�� mo-
lecules sta�ilize the open conformation and facilitate 
the recruitment of the adaptor molecule Fas-Asso-
ciated-Death-Domain �FADD/MORT-�� [��]. FADD 
�inds to the intracellular DD of CD�� �y homotypic 
interactions via its own DD [��]. FADD contains an-
other protein�protein interaction module of a�out 
8� residues in the N-terminal domain — death effector 
domain �DED� [��]. Interaction of FADD protein with the 
CD�� or other DD-containing receptors unmasks the 
DED� which allows it to recruit procaspases-8a/� and 
-�� [��]� and also the cellular FLICE/caspase-8-like 
inhi�itory protein �c-FLIP� [��� ��� ��]. It �ecame clear 
that at the DI�C two DED-containing proteins �procas-
pase-8 and c-FLIP� play the role of main molecular 
switches for the apoptotic versus non-apoptotic sig-
naling. Pro-apoptotic as well as survival functions were 
reported for �oth procaspase-8 and c-FLIP. Procas-
pase-8� c-FLIP proteins and their cleavage products 
were demonstrated to play a prominent role in the 
regulation of CD��-mediated pro-apoptotic as well 
as survival signaling �NF-κB� MAPK� etc.� [����6].
There are evidences for the assem�ling of second-
ary cytosolic DI�C — complex II after CD�� ligation. 
This complex does not contain the CD�� receptor 
and does not depend on receptor internalization [�7].
DI�C serves as a platform for the oligomerization 
of procaspase-8 and allows two procaspase-8 homodi-
mers to �e in the close proximity leading to the initial 
activation of procaspase-8 followed �y its su�sequent 
cleavage. During this process procaspase-8 undergoes 
a su�strate specificity switch [�8]. Procaspase-8 at the 
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DI�C has two su�strates: itself and c-FLIP. At the same 
time fully activated caspase-8 can cleave the apoptotic 
su�strates� such as effector caspases and Bid [�8]. 
It has �een recently reported using transgenic mice 
that the pertur�ation of the caspase-8 cleavage site 
a�rogates its pro-apoptotic function without influencing 
its non-apoptotic function [��].
Posttranslational modifications play an important 
role in regulation of procaspase-8 activity. Phosphory-
lation of procaspase-8 at the catalytic su�units has 
�een shown to inhi�it its pro-apoptotic activity� likely 
�y interfering with processing of procaspase-8 [��� 
��]. However� polyu�iquitination of procaspase-8 at the 
DI�C sta�ilize the active caspase-8 heterotetramer 
and plays the pro-apoptotic role [��].
Regulation of caspase-8 pro-apoptotic function 
may also �e exerted on the level of gene transcription. 
For example� the expression of caspase-8 is down-
regulated in tumor cells of neuro�lastomas due 
to methylation of its promoter region. In this case the 
transcription of the gene is downregulated and cells 
express reduced levels of the caspase-8 protein. 
As a result the activation of apoptotic pathways that 
require caspase-8 is �locked [��].
By cleavage of c-FLIP procaspase-8 creates an-
other molecular switch at the DI�C. Procaspase-8 ac-
tivity is required for generation of c-FLIP N-terminal 
cleavage products p��-FLIP and p��-FLIP. Three 
c-FLIP isoforms� long �c-FLIPL�� short �c-FLIP��� and 
Raji �c-FLIPR�� and two procaspase-8 generated 
cleavage products �p��-FLIP and p��-FLIP� have 
�een characterized so far [��]. All c-FLIP proteins 
are a�le to �lock procaspase-8 activation at DI�C� 
there�y exert the survival function� especially via 
activation of NF-κB pathway [��� �6]. The exception 
is the c-FLIPL isoform� which may also induce procas-
pase-8 activation [��� �6]. Both c-FLIPL downregula-
tion and overexpression were demonstrated to �lock 
procaspase-8 processing. The ratio of c-FLIP to pro-
caspase-8 at the DI�C plays the central role in the 
regulation of MAPK induction �y defining the amount 
of active caspase-8 generated at the DI�C [�6].
Procaspase-8 activity has �een suggested 
to �e indispensi�le for MAPK activation� and also for 
the initiation of other non-apoptotic pathways [�8]. 
In tumor cells resistant to CD��-induced apoptosis 
�e.g.� MCF7-Fas-Bcl-xL� the triggering of CD�� was 
reported to result in activation of survival pathways in-
volving NF-κB� MAPK �ERK�/�� p�8� c-Jun N-terminal 
kinase�� and Akt [��]. p��-FLIP� which is generated 
�y procaspase-8 at the DI�C� interacts with compo-
nents of the TNFR-mediated NF-κB activation pathway� 
TNFR-associated factor � �TRAF��� TRAF� and RIP� 
which together promote NF-κB activation. In addition� 
p��-FLIP generated at the DI�C might directly activate 
the IKK complex leading to NF-κB induction [��].
Upon DI�C formation� two CD�� apoptotic signaling 
pathways were revealed that correspond to two types 
of cells [��]. Type I cells are characterized �y high lev-
els of CD�� DI�C formation and increased amounts 
of active caspase-8. Activated caspase-8 directly 
leads to the activation of downstream effector caspas-
es-� and -7. Lower levels of DI�C formation and as a re-
sult lower levels of active caspase-8 were found in type 
II cells. For these cells an additional amplification loop 
is needed for effective apoptotic signaling that involves 
the cleavage �y caspase-8 of the Bcl-� family protein 
Bid to generate truncated �t� Bid and su�sequent tBid-
mediated release of cytochrome c from mitochondria. 
Upon release of cytochrome c from mitochondria� 
it �inds to the cytosolic adaptor protein Apaf� �apoptotic 
protease activating factor �� to facilitate the formation 
of apoptosome followed �y recruitment and activation 
of procaspase-�� which in turn cleaves downstream 
effector caspases [��]. It should �e noticed� that type 
I cells are characte rized �y rapid CD�� internalization 
while it was delayed in type II cells [��]. The definition 
of type I and II cells and also assem�ly of complex 
II could �e applied to other DRs. 
Another molecular switch of CD��-mediated sig-
naling on the level of DI�C may �e provided �y RIP�� 
DD-containing receptor-interacting protein � [�6� �7]. 
This serine-threonine kinase �inds to all DRs as well 
as to DD-containing adaptors. RIP� posttranslational 
modifications like phosphorylation and u�iquitination 
regulate this kinase involvement in TNFR� signaling 
cascades that determine cell fate. RIP� phosphorylation 
is necessary for ERK activation� and polyu�iquitination 
is critical for NF-κB activation� while deu�iquitination 
of RIP� results in enhanced formation of RIP�/FADD/
procaspase 8 complexes� followed �y caspase 8 ac-
tivation and apoptosis [�6]. The RIP� kinase domain 
is important for survival signals such as those mediated 
�y ERK� while RIP� DD is required for TNF-induced cell 
death [�6��8]. The RIP� involvement in CD��-medi-
ated signaling is less clarified� however it was shown 
that RIP� DD is critical for RIP� and CD�� association 
to mediate anoikis and RIP� shuttles �etween CD��-
mediated cell death and integrin/focal adhesion kinase-
mediated survival pathways [�8]. Also RIP� contri�utes 
to CD��-mediated NF-κB activation [�6]. Moreover� 
RIP� plays a central role in CD��-mediated necrosis 
in the a�sence of caspase-8 [��� �6].
Mutations in the CD95 gene are frequently found 
in human cancers and the vast majority of the mu-
tations were reported for DD coding region �exon 
8 or the part of exon �� [��]. Although a large num�er 
of tumors have congenital or somatic mutations in the 
CD�� DD� the loss of heterozygocity was found quite 
rarely. Thus� maintaining one wild-type receptor may 
confer an oncogenic advantage [��]. This advantage 
is likely due to the fact that CD��-induced apoptosis 
requires two functional CD�� alleles in order to ensure 
efficient DI�C formation [��]. In contrast� the signal-
ing threshold to activate NF-κB is significantly lower 
and can �e achieved even in the presence of only one 
functional CD�� allele [��].
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MITOCHONDRIAL LEVEL
Regulation of CD��-induced apoptosis on mito-
chondrial level would apply for Type II cells� which 
require activation loop for signal amplification. Apop-
tosis could �e �locked at the level of mitochondria 
�y the expression of the anti-apoptotic mem�ers of the 
Bcl-� family proteins �Bcl-�� Bcl-xL�. Briefly� these 
proteins as well as pro-apoptotic Bcl-� family proteins 
�Bax� Bak� Bcl-x�� etc.� have an opposite effect on mi-
tochondrial outer mem�rane permea�ilization �y regu-
lating the inner mitochondrial permea�ility transition 
pore [6�]. Anti-apoptotic Bcl-� family proteins prevent 
the formation of the mitochondrial apoptosis-induced 
channel required for cytochrome c release from mito-
chondria and apoptosome formation [6�].
Mitochondria-dependent level of apoptosis regula-
tion also involves the family of inhi�itors of apoptosis 
�IAP� [6�� 6�]. These are functionally and structurally 
related proteins� which could �ind effector caspases 
and serve as endogenous IAP. A common feature 
of all IAPs is the presence of a Baculovirus IAP Repeat 
�BIR� 7� amino acid domain in one to three copies. 
The human IAP family consists of 8 mem�ers� and 
IAP homologs were identified in numerous organisms 
[6�� 6�]. The most descri�ed family mem�er is XIAP 
�X-linked inhi�itor of apoptosis�. XIAP directly �ind 
to caspase-�� caspase-7 and caspase-� and �y this 
�lock their function. Activity of XIAP is �locked �y �ind-
ing to �MAC �second mitochondria-derived activator 
of caspase� and HTRA� �high temperature requirement 
protein A�� proteins released from mitochondria upon 
induction of pro-apoptic stimuli. Other IAP proteins are 
not potent inhi�itors of caspases. Instead� they �ind 
to �MAC with high affinities and prevent it from �locking 
XIAP-mediated inhi�ition [6�� 6�]. �everal IAP proteins 
are crucial regulators of NF-κB� particularly c-IAP� and 
c-IAP� [6�].
Mem�ers of the IAP protein family are frequently 
deregulated in cancer and contri�ute to chemoresis-
tance and treatment failure [6�]. Genetic evidence 
indicates that cIAP1 and cIAP2 are proto-oncogenes 
that are affected �y chromosomal a�errations in can-
cers including esophageal carcinoma� hepatocellular 
carcinoma� cervical cancer� liver cancer� medullo�las-
toma� glio�lastoma� non-small-cell lung cancer� small 
cell lung cancer and pancreatic cancer [6�]. High level 
of XIAP expression significantly correlated with poor 
clinical outcome for patients with diffuse large B cell 
lymphoma� clear-cell renal cell carcinoma� �ladder 
cancer� hepatocellular carcinoma� �reast carcinoma� 
cervical squamous cell carcinoma [6�]. Taking into ac-
count the important role of IAPs for tumor cell survival� 
these proteins �ecame an attractive targets for thera-
peutic intervention in human malignancies [6�� 6�].
MicroRNA LEVEL
MicroRNAs �miRNAs�� a class of endogenous non-
coding highly conserved RNAs� are involved in regula-
tion of gene activity at the post-transcriptional level. 
They negatively regulate translation or directly cleave 
the targeted mRNA. MiRNAs are highly expressed 
u�iquitous regulators� which were shown to �e en-
gaged �implicated� in regulation of cell differentiation� 
proliferation and programmed death. It was shown that 
several miRNAs are a�le to control pro- or antiapoptot-
ic processes and� importantly� tumorigenesis [66� 67]. 
A miRNA gene array analysis revealed the differential 
miRNAs expression �etween Type I and Type II cells: 
the mem�ers of let-7 family were preferentially ex-
pressed in Type II cells [66]. Also� miRNA-�� indirectly 
targets the CD�� expression in cancer cells [67]. And 
recently the miRNA direct target of CD��-mediated 
pathway was found. It was shown that antiapoptotic 
cytosolic protein Fas apoptosis inhi�itory molecule 
�FAIM� is an immediate miRNA-���� target [68]. The 
molecular mechanisms of FAIM action are not under-
stood in detail [6�]. However� it is clear that it is working 
upstream from PARP� caspase-8 and caspase-� [7�]. 
It was suggested that CD�� ligation induces the re-
lease of splice variant FAIM-L from CD��� allows the 
�inding of FADD and caspase-8� and leads to apopto-
sis activation [7�]. Post-transcriptional level of apop-
totic cell-signaling has not �een extensively explored 
nevertheless increasing evidences are indicating that 
miRNAs may serve as a controller of receptor mediated 
apoptosis in normal and tumor cells.
We learned the important lessons from studies 
on CD�� receptor signaling that revealed the versatile 
principles of cell fate regulation via DRs. First� the DRs 
are the dual-function receptors. �econd� molecular 
network that regulates cell death and survival is under 
the multilevel control. Third� at least five levels of life-
death cell regulation can �e tracked: extracellular� 
mem�rane� DI�C� mitochondrial� and miRNA. Fourth� 
the signal transduction pathways� which regulate cell 
life and death decisions� have illusory �oundaries. 
Fifth� the cellular outcome of signaling via DRs de-
pends on other extracellular signals and availa�ility 
of different intracellular components of signal-trans-
duction pathways.
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